Do analysts recommend MDP or CPH?

Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential downside of 0.99%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate FIRE or MDP?

Given Supreme Cannabis' higher possible upside, equities research analysts clearly believe Supreme Cannabis is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supreme Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Do analysts recommend ACB or MDP?

Aurora Cannabis presently has a consensus price target of C$7.17, suggesting a potential upside of 75.22%. Given Aurora Cannabis' higher possible upside, equities analysts clearly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Do analysts prefer MDP or EPI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 ESSA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer ICC or MDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ICC Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Medexus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Which has better earnings & valuation, ICC or MDP?

Medexus Pharmaceuticals has higher revenue and earnings than ICC Labs. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ICC Labs C$533.68K 419.04 C$2.35M C$0.02 95.29 Medexus Pharmaceuticals C$99.33M 1.64 C$3.26M -C$0.07 N/A

Medexus Pharmaceuticals (MDP) Competitors

C$5.14 -0.09 (-1.72%)

As of 07/3/2026 03:59 PM Eastern

Compare

MDP vs. CPH, FIRE, ACB, EPI, and ICC

Should you buy Medexus Pharmaceuticals stock or one of its competitors? MarketBeat compares Medexus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medexus Pharmaceuticals include Cipher Pharmaceuticals (CPH), Supreme Cannabis (FIRE), Aurora Cannabis (ACB), ESSA Pharma (EPI), and ICC Labs (ICC). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Medexus Pharmaceuticals (TSE:MDP) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential downside of 0.99%. Given Cipher Pharmaceuticals' higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cipher Pharmaceuticals has lower revenue, but higher earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$99.33M	1.64	C$3.26M	-C$0.07	N/A
Cipher Pharmaceuticals	C$50.94M	8.56	C$11.41M	C$1.19	14.43

In the previous week, Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
Cipher Pharmaceuticals	Neutral

3.3% of Medexus Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by company insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Medexus Pharmaceuticals has a beta of 0.216596, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 1.104631, indicating that its stock price is 10% more volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Medexus Pharmaceuticals' net margin of -2.41%. Cipher Pharmaceuticals' return on equity of 25.69% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-2.41%	-4.64%	4.89%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

Summary

Cipher Pharmaceuticals beats Medexus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Supreme Cannabis (TSE:FIRE) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Supreme Cannabis has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -2.41%. Supreme Cannabis' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supreme Cannabis	N/A	N/A	N/A
Medexus Pharmaceuticals	-2.41%	-4.64%	4.89%

3.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Medexus Pharmaceuticals has higher revenue and earnings than Supreme Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Supreme Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supreme Cannabis	C$53.29M	0.00	-C$23.65M	-C$0.03	N/A
Medexus Pharmaceuticals	C$99.33M	1.64	C$3.26M	-C$0.07	N/A

In the previous week, Supreme Cannabis' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Supreme Cannabis	Neutral
Medexus Pharmaceuticals	Neutral

Given Supreme Cannabis' higher possible upside, equities research analysts clearly believe Supreme Cannabis is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supreme Cannabis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Summary

Medexus Pharmaceuticals beats Supreme Cannabis on 7 of the 12 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Aurora Cannabis (TSE:ACB) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Aurora Cannabis presently has a consensus price target of C$7.17, suggesting a potential upside of 75.22%. Given Aurora Cannabis' higher possible upside, equities analysts clearly believe Aurora Cannabis is more favorable than Medexus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Medexus Pharmaceuticals has a net margin of -2.41% compared to Aurora Cannabis' net margin of -12.13%. Medexus Pharmaceuticals' return on equity of -4.64% beat Aurora Cannabis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-12.13%	-7.25%	-1.87%
Medexus Pharmaceuticals	-2.41%	-4.64%	4.89%

In the previous week, Aurora Cannabis had 1 more articles in the media than Medexus Pharmaceuticals. MarketBeat recorded 1 mentions for Aurora Cannabis and 0 mentions for Medexus Pharmaceuticals. Medexus Pharmaceuticals' average media sentiment score of 0.00 beat Aurora Cannabis' score of -1.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aurora Cannabis	Negative
Medexus Pharmaceuticals	Neutral

Aurora Cannabis has a beta of 0.174133, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Medexus Pharmaceuticals has a beta of 0.216596, meaning that its stock price is 78% less volatile than the broader market.

Medexus Pharmaceuticals has lower revenue, but higher earnings than Aurora Cannabis. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	C$320.59M	0.79	-C$44.16M	-C$2.14	N/A
Medexus Pharmaceuticals	C$99.33M	1.64	C$3.26M	-C$0.07	N/A

4.1% of Aurora Cannabis shares are held by institutional investors. Comparatively, 3.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Medexus Pharmaceuticals beats Aurora Cannabis on 11 of the 17 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to ESSA Pharma?

Medexus Pharmaceuticals (TSE:MDP) and ESSA Pharma (CVE:EPI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Medexus Pharmaceuticals' average media sentiment score of 0.00 equaled ESSA Pharma'saverage media sentiment score.

Company	Overall Sentiment
Medexus Pharmaceuticals	Neutral
ESSA Pharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
ESSA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Medexus Pharmaceuticals has higher revenue and earnings than ESSA Pharma. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medexus Pharmaceuticals	C$99.33M	1.64	C$3.26M	-C$0.07	N/A
ESSA Pharma	N/A	N/A	N/A	-C$0.99	N/A

3.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ESSA Pharma has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -2.41%. ESSA Pharma's return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medexus Pharmaceuticals	-2.41%	-4.64%	4.89%
ESSA Pharma	N/A	N/A	N/A

Summary

Medexus Pharmaceuticals beats ESSA Pharma on 7 of the 10 factors compared between the two stocks.

How does Medexus Pharmaceuticals compare to ICC Labs?

ICC Labs (CVE:ICC) and Medexus Pharmaceuticals (TSE:MDP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

3.3% of Medexus Pharmaceuticals shares are held by institutional investors. 9.1% of Medexus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Medexus Pharmaceuticals has higher revenue and earnings than ICC Labs. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICC Labs	C$533.68K	419.04	C$2.35M	C$0.02	95.29
Medexus Pharmaceuticals	C$99.33M	1.64	C$3.26M	-C$0.07	N/A

In the previous week, ICC Labs' average media sentiment score of 0.00 equaled Medexus Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ICC Labs	Neutral
Medexus Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICC Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Medexus Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

ICC Labs has a net margin of 0.00% compared to Medexus Pharmaceuticals' net margin of -2.41%. ICC Labs' return on equity of 0.00% beat Medexus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ICC Labs	N/A	N/A	N/A
Medexus Pharmaceuticals	-2.41%	-4.64%	4.89%

Summary

Medexus Pharmaceuticals beats ICC Labs on 7 of the 12 factors compared between the two stocks.

Get Medexus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDP vs. The Competition

Export

Metric	Medexus Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$165.58M	C$6.60B	C$7.18B	C$13.07B
Dividend Yield	N/A	2.83%	2.66%	6.18%
P/E Ratio	-73.43	5.11	28.02	36.51
Price / Sales	1.64	1,653.39	537.00	10.34
Price / Cash	N/A	10.18	49.26	82.29
Price / Book	3.36	10.83	10.96	4.52
Net Income	C$3.26M	C$20.27B	C$3.57B	C$299.09M
7 Day Performance	22.38%	1.30%	2.12%	1.85%
1 Month Performance	31.46%	-1.17%	5.25%	1.71%
1 Year Performance	65.27%	9.82%	33.29%	36.40%

Medexus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDP Medexus Pharmaceuticals	N/A	C$5.14 -1.7%	N/A	+65.3%	C$165.58M	C$99.33M	N/A	98
CPH Cipher Pharmaceuticals	N/A	C$16.72 +1.5%	C$17.00 +1.7%	+26.5%	C$424.54M	C$50.94M	14.05	5
FIRE Supreme Cannabis	N/A	N/A	N/A	N/A	C$259.40M	C$53.29M	N/A	400
ACB Aurora Cannabis	2.1001 of 5 stars	C$3.93 -3.0%	C$7.67 +95.1%	-34.1%	C$243.43M	C$320.59M	N/A	1,073	Negative News Analyst Forecast
EPI ESSA Pharma	N/A	C$8.20 +7.2%	N/A	+0.0%	C$237.87M	N/A	N/A	25

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MDP) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, FIRE, ACB, EPI, and ICC

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Summary

How does Medexus Pharmaceuticals compare to ESSA Pharma?

Summary

How does Medexus Pharmaceuticals compare to ICC Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medexus Pharmaceuticals (MDP) Competitors

MDP vs. CPH, FIRE, ACB, EPI, and ICC

How does Medexus Pharmaceuticals compare to Cipher Pharmaceuticals?

Do analysts recommend MDP or CPH?

Which has stronger earnings and valuation, MDP or CPH?

Does the media favor MDP or CPH?

Do insiders and institutionals believe in MDP or CPH?

Which has more risk & volatility, MDP or CPH?

Is MDP or CPH more profitable?

Summary

How does Medexus Pharmaceuticals compare to Supreme Cannabis?

Is FIRE or MDP more profitable?

Do institutionals & insiders believe in FIRE or MDP?

Which has higher valuation & earnings, FIRE or MDP?

Does the media favor FIRE or MDP?

Do analysts rate FIRE or MDP?

Summary

How does Medexus Pharmaceuticals compare to Aurora Cannabis?

Do analysts recommend ACB or MDP?

Is ACB or MDP more profitable?

Does the media prefer ACB or MDP?

Which has more volatility & risk, ACB or MDP?

Which has better valuation & earnings, ACB or MDP?

Do institutionals & insiders hold more shares of ACB or MDP?

Summary

How does Medexus Pharmaceuticals compare to ESSA Pharma?

Does the media favor MDP or EPI?

Do analysts prefer MDP or EPI?

Which has higher earnings and valuation, MDP or EPI?

Do institutionals and insiders believe in MDP or EPI?

Is MDP or EPI more profitable?

Summary

How does Medexus Pharmaceuticals compare to ICC Labs?

Do insiders and institutionals believe in ICC or MDP?

Which has better earnings & valuation, ICC or MDP?

Does the media favor ICC or MDP?

Do analysts prefer ICC or MDP?

Is ICC or MDP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDP vs. The Competition

Medexus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools